SCYNEXIS Stock

SCYNEXIS Equity Ratio

The Equity Ratio of SCYNEXIS (SCYX) as of Aug 4, 2026 is 60.76 %. In the previous year, Equity Ratio was 56.82 % — a change of 6.94% (higher).

Equity Ratio

60.76 %

YoY

6.94%

Last updated:

Equity Ratio of SCYNEXIS is 2026 60.76 % . Equity Ratio of SCYNEXIS was 2025 56.82 % . It decreases by 6.94% higher compared to the previous year.
Access this data via the Eulerpool API

SCYNEXIS Stock analysis

What does SCYNEXIS do? SCYNEXIS Inc is a biopharmaceutical company that focuses on the discovery and development of novel therapeutics for serious infectious diseases and cancer. The company was founded in 2000 and is headquartered in New Jersey, USA. SCYNEXIS is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SCYNEXIS stock

Equity Ratio of SCYNEXIS is 60.76 % in 2026.

Equity Ratio of SCYNEXIS changed from 56.82 % to 60.76 %, representing a 6.94% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Equity Ratio SCYNEXIS since 2006 – with annual values, charts, and detailed analysis.

The equity ratio measures the proportion of total assets financed by shareholders' equity. Higher ratios indicate stronger financial independence and lower leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Ratio's SCYNEXIS with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Leverage — SCYNEXIS

All Key Metrics — SCYNEXIS